Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 11/20 | 0.61 |
| ▸ | CDK2 | P24941 | 11/20 | 0.61 |
| ▸ | CDK5 | Q00535 | 11/20 | 0.61 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | OGA | O60502 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5780845 | 0.95 | CCNE1 (0.65) | CCNE1CDK2CDK5CDK5R1ALDH1A1 | |
| SCHEMBL895339 | 0.79 | CCNE1 (0.69) | CCNE1CDK2CDK5KMT2AALDH1A1 | |
| SCHEMBL1895794 | 0.79 | CCNE1 (0.65) | CCNE1CDK2CDK5KMT2AALDH1A1 | |
| SCHEMBL32671861 | 0.79 | CCNE1 (0.65) | CCNE1CDK2CDK5KMT2AALDH1A1 | |
| SCHEMBL13499905 | 0.79 | CCNE1 (0.65) | CCNE1CDK2CDK5KMT2AALDH1A1 | |
| SCHEMBL894206 | 0.78 | RAB9A (0.58) | KMT2AALDH1A1MEN1POLBMIF | |
| SCHEMBL6281751 | 0.78 | CDK2 (0.90) | CCNE1CDK2CDK5CDK5R1KMT2A | |
| SCHEMBL13453223 | 0.78 | CCNE1 (0.67) | CCNE1CDK2CDK5KMT2AALDH1A1 | |
| SCHEMBL23240244 | 0.76 | CCNE1 (0.64) | CCNE1CDK2CDK5KMT2AALDH1A1 | |
| SCHEMBL21533626 | 0.76 | CCNE1 (0.61) | CCNE1CDK2CDK5KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | CLIC1, HCCS, CNR1 | CCNE1 768/4885CDK2 941/4885CDK5 2440/4885 |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | CBR1, CLIC1, RER1 | CCNE1 684/4885CDK2 747/4885CDK5 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.